Kinfo
Niagen Bioscience Inc. logo

Niagen Bioscience Inc.

CDXCNASDAQHealthcare·US · USD
$3.12
+0.08 (+2.63%)
Prices as of August 7, 2026 · market closed

Price

Key statistics

Valuation
Market cap241.27M USD
Enterprise value199.41M USD
Trailing P/E71.55
Forward P/E65.58
PEG ratio-0.09
Price / sales2.42
Price / book4.39
Profitability
Gross margin63.42%
Operating margin7.76%
Profit margin61.84%
Return on assets12.52%
Return on equity18.55%
Income (TTM)
Revenue99.60M USD
Gross profit61.59M USD
EBITDA14.69M USD
Net income8.55M USD
Diluted EPS$0.00
Rev. growth (YoY)4.66%
Balance sheet
Total cash0.00 USD
Total debt3.52M USD
Debt / equity0.06
Current ratio3.66
Book value / share$0.71
Cash flow (TTM)
Operating cash flow12.22M USD
Levered free cash flow8.55M USD
Shares & price
Shares outstanding78.43M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$0.00
200-day MA$0.00
52-week high$10.52
52-week low$2.87
Earnings (EPS)
DateEst.ActualSurprise2026-06-173.123.16+1.28%2026-03-10-0.27-0.04+85.19%2026-01-300.400.47+17.50%2025-09-240.010.04+300.00%
About Niagen Bioscience Inc.

Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California. The company specializes in advancing NAD+ science to support cellular health and healthy aging through its proprietary Niagen platform, a patented NAD+-boosting ingredient known as nicotinamide riboside (NR). Niagen powers leading brands such as Tru Niagen, an oral supplement for consumer use, and Niagen Plus, which includes pharmaceutical-grade intravenous and injectable formulations available at clinics across the U.S. Niagen Bioscience Inc. operates ISO-accredited laboratories and maintains a reference standards business providing natural products, phytochemicals, and botanical reference materials for quality assurance in food, supplements, and research. It also runs the ChromaDex External Research Program, supplying high-quality NAD+ precursors to academic and government researchers worldwide. The company discovers, develops, and commercializes proprietary ingredient technologies targeting dietary supplements, food, beverages, skin care, and pharmaceutical markets, emphasizing science-backed innovation, clinical research, and regulatory compliance.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert N. Fried
Employees
117
Headquarters
Los Angeles, CA, United States

Frequently asked questions about Niagen Bioscience Inc.